Description of the GiACTA trial (Stone et al, N. Engl. J. Med. 2017), a Phase III clinical trial of tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA).
Description of the MIRRA trial (Wechsler et al, N. Engl. J. Med. 2017), a Phase III clinical trial of mepolizumab (Nucala) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss Syndrome).
How do the IL-5 inhibitors Cinqair (reslizumab), Fasenra (benralizumab), and Nucala (mepolizumab) work? How do they control eosinophils?